For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 19 results
Author Title [ Type(Asc)] Year
Filters: Author is Klasse, Per Johan  [Clear All Filters]
Journal Article
Veazey RS, Ketas TA, Klasse PJohan, Davison DK, Singletary M, Green LC, Greenberg ML, Moore JP.  2008.  Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.. Proc Natl Acad Sci U S A. 105(30):10531-6.
Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YKenneth, Depetris R, Marozsan AJ, Sanders RW et al..  2011.  Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.. Proc Natl Acad Sci U S A. 108(28):11440-5.
Melchers M, Bontjer I, Tong T, P Y Chung N, Klasse PJohan, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC et al..  2012.  Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.. J Virol. 86(5):2488-500.
R Malcolm K, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJohan et al..  2012.  Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.. Antimicrob Agents Chemother. 56(5):2251-8.
W Horne S, Johnson LM, Ketas TJ, Klasse PJohan, Lu M, Moore JP, Gellman SH.  2009.  Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.. Proc Natl Acad Sci U S A. 106(35):14751-6.
Anastassopoulou CG, Ketas TJ, Klasse PJohan, Moore JP.  2009.  Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.. Proc Natl Acad Sci U S A. 106(13):5318-23.
Anastassopoulou CG, Ketas TJ, Depetris RS, Thomas AM, Klasse PJohan, Moore JP.  2011.  Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.. Virology. 413(1):47-59.
Veazey RS, Klasse PJohan, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ et al..  2005.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.. Nature. 438(7064):99-102.
Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJohan, Moore JP.  2005.  Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.. Nat Med. 11(12):1293-4.
Forbes CJ, Lowry D, Geer L, Veazey RS, Shattock RJ, Klasse PJohan, Mitchnick M, Goldman L, Doyle LA, Muldoon BCO et al..  2011.  Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.. J Control Release. 156(2):161-9.
Berro R, Klasse PJohan, Lascano D, Flegler A, Nagashima KA, Sanders RW, Sakmar TP, Hope TJ, Moore JP.  2011.  Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.. J Virol. 85(16):8227-40.
Burton DR, Hessell AJ, Keele BF, Klasse PJohan, Ketas TA, Moldt B, D Dunlop C, Poignard P, Doyle LA, Cavacini L et al..  2011.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.. Proc Natl Acad Sci U S A. 108(27):11181-6.
Pugach P, Ray N, Klasse PJohan, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP.  2009.  Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.. Virology. 387(2):296-302.
Klasse PJohan, Sanders RW, Cerutti A, Moore JP.  2012.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses. 28(1):1-15.
Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L et al..  2015.  HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.. Science. 349(6244):aac4223.
Banerjee K, Andjelic S, Klasse PJohan, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP.  2009.  Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.. Virology. 389(1-2):108-21.
Ketas TJ, Holuigue S, Matthews K, Moore JP, Klasse PJohan.  2012.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.. Virology. 422(1):22-36.
Ketas TJ, Schader SM, Zurita J, Teo E, Polonis V, Lu M, Klasse PJohan, Moore JP.  2007.  Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.. Virology. 364(2):431-40.
Klasse PJohan, Shattock R, Moore JP.  2008.  Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission.. Annu Rev Med. 59:455-71.